زيمبابوي -
الإنجليزية -
Medicines Control Authority
afinnitor
novartis pharma services ag - everolimus - tablet; oral - 5 mg
زيمبابوي -
الإنجليزية -
Medicines Control Authority
asunra
novartis pharma services ag - deferasirox - tablet; oral - 400 mg
زيمبابوي -
الإنجليزية -
Medicines Control Authority
asunra
novartis pharma services ag - deferasirox - tablet; oral - 100 mg
زيمبابوي -
الإنجليزية -
Medicines Control Authority
galvus met
novartis pharma services ag - metformin hydrochloride; vildagliptin - tablet, coated; oral - 50; 850 mg
زيمبابوي -
الإنجليزية -
Medicines Control Authority
patizra
novartis pharma services ag - ranibizumab - solution; injection - 10mg/ml
زيمبابوي -
الإنجليزية -
Medicines Control Authority
tasigna
novartis pharma services ag - nilotinib hydrochloride monohydrate - capsule; oral - 150 mg
زيمبابوي -
الإنجليزية -
Medicines Control Authority
tasigna
novartis pharma services ag - nilotinib hydrochloride monohydrate - capsule; oral - 200 mg
زيمبابوي -
الإنجليزية -
Medicines Control Authority
coartem
novartis pharma services ag - artemether; lumefantrine - tablet; oral - 20; 120mg
أستراليا -
الإنجليزية -
Department of Health (Therapeutic Goods Administration)
ciproxin hc ear drops 0.2% ciprofloxacin (as hydrochloride) and 1% hydrocortisone ear drops
novartis pharmaceuticals australia pty ltd - ciprofloxacin, quantity: 2 mg/ml; hydrocortisone, quantity: 10 mg/ml - ear drops, suspension - excipient ingredients: polysorbate 20; sodium acetate; glacial acetic acid; benzyl alcohol; hydrogenated soy phosphatidylcholine; sodium chloride; polyvinyl alcohol; purified water - for the treatment of acute bacterial otitis externa, caused by organisms susceptible to ciprofloxacin (see pharmacology), in adults and children aged 2 years and older.
ماليزيا -
الإنجليزية -
NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)
tasigna 150mg capsule
novartis corporation (malaysia) sdn. bhd. - nilotinib hydrochloride monohydrate -